Table 1 Baseline characteristics of patients with IgD MM, LCMM and healthy CTRs
From: N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma
M protein type | IgD MM | LCMM | Healthy CTR |
|---|---|---|---|
(κ 1, λ 19) | (κ 19, λ 22) | (n = 42) | |
Male (%) | 12 (60.0%) | 26 (63.4%) | 25 (59.5%) |
Age | 56.75 ± 9.51 | 58.17 ± 12.14 | 59.14 ± 5.90 |
ISS stage I | 4 (20.0%) | 11 (26.8%) | / |
ISS stage II | 5 (25.0%) | 3 (7.3%) | / |
ISS stage III | 11 (55.0%) | 27 (65.9%) | / |
Durie Salmon stage IIIA | 16 (80.0%) | / | / |
Durie Salmon stage IIIB | 4 (20.0%) | / | / |
Haemoglobin | 89.50 ± 20.61 | 100.28 ± 28.46 | 146.34 ± 9.42 |
Total protein | 62.95 ± 8.83 | 60.88 ± 7.89 | 76.24 ± 3.87 |
Albumin | 36.33 ± 4.60 | 39.23 ± 5.51 | 47.17 ± 2.18 |
Serum FLC ratio | 2.62 ± 1.74 | / | / |
Urine FLC ratio | 204.47 ± 262.98 | / | / |
SPE positive (%) | 13 (65.0%) | 11 (26.8%) | / |
IFE positive (%) | 18 (90.0%) | 23 (56.1%) | / |
Bone lesions (%) | 14 (70.0%) | / | / |
Extramedullary infiltration (%) | 3 (15.0%) | / | / |